<DOC>
	<DOCNO>NCT01659515</DOCNO>
	<brief_summary>The primary purpose protocol make arbekacin available treatment patient infection cause multidrug-resistant organism treatment antibiotic use due unavailability , intolerance , contraindication , treatment non-response .</brief_summary>
	<brief_title>Arbekacin Treatment Adult Patients With Infections Caused Multidrug-resistant Bacteria</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Habekacin</mesh_term>
	<mesh_term>Dibekacin</mesh_term>
	<criteria>1 . Subject military health care beneficiary least 18 year age ; 2 . Subject Walter Reed National Military Medical Center patient deem primary medical surgical team bacterial infection respiratory tract , bloodstream , skin , soft tissue , bone , genitourinary tract ; 3 . Subject allergic intolerant antibiotic infective organism susceptible ; Or The use antibiotic subject 's infective organism susceptible contraindicate ; Or Subject 's infective organism isolate multidrugresistant ( MDR ) bacterium define follow : Gramnegative bacterium nonsusceptible index antibiotic within 3 6 antibiotic class include aminoglycosides ( amikacin , gentamicin , tobramycin ) , betalactam/betalactam inhibitor combination ( piperacillintazobactam , amoxicillinclavulanate ) , carbapenems ( imipenem , ertapenem ) , fluoroquinolones ( ciprofloxacin , levofloxacin ) , cephalosporin ( ceftazidime , cefepime , ceftriaxone ) , sulbactam ( ampicillinsulbactam ) ; Extended Spectrum βlactamase ( ESBL ) produce Gramnegative bacterium ; Carbapenemase resistant Enterobacteriaceae ; Cephalosporin resistant Klebsiella specie ; Methicillinresistant Staphylococcus aureus ( MRSA ) ; Vancomycin resistant Enterococcus specie ; Staphylococcus aureus nonsusceptible vancomycin . 4 . Subject 's infective organism inhibit vitro arbekacin concentration ≤ 4 μg/mL ; 5 . Subject able give write witness verbal informed consent [ An exception general requirement inform consent make base upon criterion specify 21 Code Federal Regulations 50.23 ( c ) ] ; 6 . Subject adequate venous access intravenous administration arbekacin . 7 . Sexually active female , unless surgically sterile least 1 year postmenopausal , must use effective method avoid pregnancy ( include oral implanted contraceptive , IUD , female condom , diaphragm spermicide , cervical cap , abstinence , use condom sexual partner , sterile sexual partner ) least 30 day prior receipt arbekacin must agree continue use precaution least 30 day last dose arbekacin ; subject must also negative pregnancy test within 24 hour prior initial dose arbekacin . 1 . Subject history allergy serious adverse reaction aminoglycoside antibiotic ; 2 . Subject currently participate another investigational new drug study . 3 . Subject positive serum pregnancy test breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>